Simulations Plus, Inc.

Equities

SLP

US8292141053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
45.7 USD -1.76% Intraday chart for Simulations Plus, Inc. -7.53% +2.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Slump Late Afternoon MT
Simulations Plus Says FDA Renews DILIsym Software Licenses MT
Sector Update: Tech Stocks Advance Premarket Thursday MT
Simulations Plus, Inc. Announces U.S. FDA Renews DILIsym Software Licenses CI
Sector Update: Tech MT
Simulations Plus Fiscal Q2 Earnings Beat as Revenue Rises; Maintains Full-Year Outlook; Shares Advance Premarket MT
Simulations Plus Fiscal Q2 Net Income Is Unchanged, Revenue Rises; FY Outlook Maintained; Shares Jump After Hours MT
Simulations Plus to Seek M&A CI
Transcript : Simulations Plus, Inc., Q2 2024 Earnings Call, Apr 03, 2024
(SLP) SIMULATIONS PLUS Expects Fiscal Year 2024 EPS Range $0.66 - $0.68 MT
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q2 Revenue $18.3M, vs. Street Est of $17.3M MT
Earnings Flash (SLP) SIMULATIONS PLUS Posts Q2 EPS $0.20, vs. Street Est of $0.18 MT
Simulations Plus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Simulations Plus, Inc. Declares a Cash Dividend, Payable on May 6, 2024 CI
Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Simulations Plus Insider Sold Shares Worth $798,867, According to a Recent SEC Filing MT
Simulations Plus Insider Sold Shares Worth $828,240, According to a Recent SEC Filing MT
Simulations Plus, Inc. Extends Collaboration with Major Toxicology Research Agency CI
Simulations Plus, Inc. Releases GastroPlus Version 9.9 CI
Simulations Plus Insider Sold Shares Worth $889,200, According to a Recent SEC Filing MT
Tranche Update on Simulations Plus, Inc.'s Equity Buyback Plan announced on January 4, 2023. CI
(SLP) SIMULATIONS PLUS Forecasts Fiscal Year 2024 EPS Range $0.66 - $0.68 MT
Earnings Flash (SLP) SIMULATIONS PLUS Reports Q1 Revenue $14.5M, vs. Street Est of $13.9M MT
Simulations Plus, Inc. Declares Cash Dividend, Payable on February 5, 2024 CI
Transcript : Simulations Plus, Inc., Q1 2024 Earnings Call, Jan 03, 2024
Chart Simulations Plus, Inc.
More charts
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
45.7 USD
Average target price
53.67 USD
Spread / Average Target
+17.43%
Consensus
  1. Stock Market
  2. Equities
  3. SLP Stock
  4. News Simulations Plus, Inc.
  5. Insider Trends: Insider at Simulations Plus Acquires Stock Via Option/Derivative Security, Sells Portion to Pay Tax, Selling Trend Continues